Satya Sadhan Sarangi

Real-world outcomes and immune-related adverse events with PD-1/ PD-L1 inhibitors in metastatic renal cell carcinoma: A prospective observational study

Objectives: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have changed the management of metastatic renal cell carcinoma (mRCC). Most pivotal trials come from high-income settings and include highly selected patients. Prospective real-world data from low- and...